DFTX
NASDAQDefinium Therapeutics Inc.
SectorHealth CareIndustry Medicinal Chemicals and Botanical Products
News25/Ratings5
News · 26 weeks70+163%
2025-12-282026-06-21
Mix4690d
- Other14(30%)
- Insider14(30%)
- SEC Filings12(26%)
- Analyst3(7%)
- Earnings2(4%)
- Offering1(2%)
Latest news
25 items- ANALYSTNeedham reiterated coverage on Definium Therapeutics with a new price targetNeedham reiterated coverage of Definium Therapeutics with a rating of Buy and set a new price target of $50.00 from $38.00 previously
- PRDefinium Therapeutics, Inc. Announces Proposed Public OfferingDefinium Therapeutics, Inc. (NASDAQ:DFTX) (the "Company" or "Definium"), a late-stage clinical biopharmaceutical company developing a new generation of therapeutics intended to address underlying causes of psychiatric and neurological disorders, today announced that it intends to offer and sell, subject to market conditions, $500 million of its common shares and, to certain investors, pre-funded warrants to purchase common shares in an underwritten public offering. In addition, Definium intends to grant the underwriters an option for a period of 30 days to purchase up to $75 million of its common shares at the public offering price, less underwriting discounts and commissions. All of the co
- SECSEC Form 424B5 filed by Definium Therapeutics Inc.424B5 - Definium Therapeutics, Inc. (0001813814) (Filer)
- INSIDERChief Medical Officer Karlin Daniel was granted 100,000 shares, increasing direct ownership by 24% to 513,317 units (SEC Form 4)4 - Definium Therapeutics, Inc. (0001813814) (Issuer)
- INSIDERChief Executive Officer Barrow Robert was granted 375,000 shares, increasing direct ownership by 50% to 1,127,454 units (SEC Form 4)4 - Definium Therapeutics, Inc. (0001813814) (Issuer)
- INSIDERChief Legal Officer Sullivan Mark was granted 62,500 shares, increasing direct ownership by 23% to 333,579 units (SEC Form 4)4 - Definium Therapeutics, Inc. (0001813814) (Issuer)
- INSIDERChief Financial Officer Roberts Brandi was granted 62,500 shares, increasing direct ownership by 42% to 212,500 units (SEC Form 4)4 - Definium Therapeutics, Inc. (0001813814) (Issuer)
- INSIDERChief Commercial Officer Wiley Matthew T. was granted 62,500 shares, increasing direct ownership by 54% to 177,500 units (SEC Form 4)4 - Definium Therapeutics, Inc. (0001813814) (Issuer)
- SECDefinium Therapeutics Inc. filed SEC Form 8-K: Regulation FD Disclosure, Other Events, Financial Statements and Exhibits8-K - Definium Therapeutics, Inc. (0001813814) (Filer)
- PRDefinium Therapeutics Announces Positive Topline Results from Phase 3 Emerge Study of DT120 Orally Disintegrating Tablet (ODT) in Major Depressive DisorderStudy met primary and all key secondary efficacy endpoints 8.1 point Montgomery-Åsberg Depression Rating Scale (MADRS) placebo-adjusted change from baseline at Week 6 for the primary endpoint (p<0.0001) 7.3 point MADRS placebo-adjusted change from baseline at Week 12, a secondary endpoint (p<0.0001) DT120 ODT was generally well tolerated with no serious adverse events or suicidality signal Company to host webcast today at 8:00 a.m. EDT Definium Therapeutics, Inc. ("Definium" or the "Company"), a late-stage clinical biopharmaceutical company developing a new generation of therapeutics intended to address underlying causes of psychiatric and neurological disorders, today announced p
- PRDefinium Therapeutics to Discuss Topline Results from Phase 3 Emerge Study in Major Depressive Disorder on June 22, 2026Company to host webcast tomorrow at 8:00 a.m. EDT Definium Therapeutics, Inc. ("Definium" or the "Company"), a late-stage clinical biopharmaceutical company developing a new generation of therapeutics intended to address underlying causes of psychiatric and neurological disorders, today announced that it will host a live webcast tomorrow at 8 a.m. EDT to discuss topline results from Emerge, its first randomized, double-blind, placebo-controlled Phase 3 study evaluating a single dose of DT120 ODT 100 µg in adults with major depressive disorder (MDD). Webcast Details Listeners can register for the webcast via this link. Analysts wishing to participate in the question-and-answer session
- SECSEC Form S-8 filed by Definium Therapeutics Inc.S-8 - Definium Therapeutics, Inc. (0001813814) (Filer)
- INSIDERDirector Vallone Carol A was granted 4,666 shares, increasing direct ownership by 28% to 21,210 units (SEC Form 4)4 - Definium Therapeutics, Inc. (0001813814) (Issuer)
- INSIDERDirector Crystal Roger was granted 4,666 shares, increasing direct ownership by 24% to 24,289 units (SEC Form 4)4 - Definium Therapeutics, Inc. (0001813814) (Issuer)
- INSIDERDirector Gryska David W was granted 4,666 shares, increasing direct ownership by 31% to 19,900 units (SEC Form 4)4 - Definium Therapeutics, Inc. (0001813814) (Issuer)
- INSIDERDirector Adsett Roger was granted 3,555 shares (SEC Form 4)4 - Definium Therapeutics, Inc. (0001813814) (Issuer)
- INSIDERDirector Krebs Andreas was granted 4,666 shares, increasing direct ownership by 31% to 19,773 units (SEC Form 4)4 - Definium Therapeutics, Inc. (0001813814) (Issuer)
- INSIDERDirector Bruhn Suzanne Louise was granted 4,666 shares, increasing direct ownership by 24% to 24,289 units (SEC Form 4)4 - Definium Therapeutics, Inc. (0001813814) (Issuer)
- PRDefinium Therapeutics Announces New Employee Inducement GrantsDefinium Therapeutics, Inc. ("Definium" or the "Company"), a late-stage clinical biopharmaceutical company developing a new generation of therapeutics intended to address underlying causes of psychiatric and neurological disorders, today announced the issuance of inducement grants to six newly hired non-executive employees consisting of options to purchase an aggregate of 155,480 common shares of the Company (the "Options") with effective grant dates of June 15, 2026. The Options have an exercise price equal to the closing price of Definium's common shares on the date of the grants, and will vest over a four-year period with 25% vesting on the first anniversary of the date of the grant and
- SECDefinium Therapeutics Inc. filed SEC Form 8-K: Leadership Update, Submission of Matters to a Vote of Security Holders, Financial Statements and Exhibits8-K - Definium Therapeutics, Inc. (0001813814) (Filer)
- PRDefinium Therapeutics Announces New Employee Inducement GrantsDefinium Therapeutics, Inc. ("Definium" or the "Company"), a late-stage clinical biopharmaceutical company developing a new generation of therapeutics intended to address underlying causes of psychiatric and neurological disorders, today announced the issuance of inducement grants to thirteen newly hired non-executive employees consisting of options to purchase an aggregate of 462,190 common shares of the Company (the "Options") with effective grant dates of May 18, 2026 and June 1, 2026. The Options have an exercise price equal to the closing price of Definium's common shares on the date of the respective grant, and will vest over a four-year period with 25% vesting on the first anniversar
- PRDefinium Therapeutics to Participate in the 2026 Jefferies Global Healthcare ConferenceDefinium Therapeutics, Inc. (NASDAQ:DFTX), a late-stage clinical biopharmaceutical company developing a new generation of therapeutics intended to address underlying causes of psychiatric and neurological disorders, today announced that members of the Company's management team will participate in a fireside chat at the 2026 Jefferies Global Healthcare Conference in New York on Wednesday, June 3, 2026 at 3:10 p.m. EDT. Audio webcasts and replays of available presentations will be accessible on Definium's Investor Relations website for up to 90 days following each event. About Definium Therapeutics The mission of Definium Therapeutics is to forge a new era of psychiatry by applying scie
- SECDefinium Therapeutics Inc. filed SEC Form 8-K: Other Events, Financial Statements and Exhibits8-K - Definium Therapeutics, Inc. (0001813814) (Filer)
- SECDefinium Therapeutics Inc. filed SEC Form 8-K: Other Events, Financial Statements and Exhibits8-K - Definium Therapeutics, Inc. (0001813814) (Filer)
- PRDefinium Therapeutics Announces First Patient Dosed in Ascend, the Second Phase 3 Pivotal Study of DT120 ODT in Major Depressive DisorderThe primary endpoint will measure the change from baseline in the Montgomery-Åsberg Depression Rating Scale (MADRS) score at Week 6 between DT120 Orally Disintegrating Tablet (ODT) 100 µg and placebo Ascend builds on positive Phase 2b study results in generalized anxiety disorder, which showed the potential antidepressant effects of DT120 Topline data from the 12-week double-blind period is anticipated in 2027 Definium Therapeutics, Inc. (NASDAQ:DFTX) ("Definium" or the "Company"), a late-stage clinical biopharmaceutical company developing a new generation of therapeutics intended to address the underlying causes of psychiatric and neurological disorders, today announced that the firs
DFTX FAQ
5 questionsWhere does DFTX stock trade?
Definium Therapeutics Inc. (DFTX) is listed on NASDAQ.What sector and industry is DFTX in?
Definium Therapeutics Inc. operates in the Health Care sector, Medicinal Chemicals and Botanical Products industry.What are analysts saying about DFTX?
Definium Therapeutics Inc. has had 5 recent analyst actions on file. The most recent action was from Needham: Buy on 2026-06-23. Recent price targets range from $2500.00 to $4900.00.What companies are similar to DFTX?
Notable peers in the same industry include PM (Philip Morris International Inc), BTI (British American Tobacco Industries p.l.c.), MO (Altria Group Inc.), RGC (Regencell Bioscience Holdings Limited), RLX (RLX Technology Inc.). Compare DFTX side-by-side with any of them on Quantisnow.How can I track DFTX on Quantisnow?
Quantisnow aggregates Definium Therapeutics Inc.'s SEC filings, analyst ratings, insider transactions, FDA approvals, and press releases the moment they hit the wire (Wall Street's wire, on your screen.). Follow DFTX to receive live email and push alerts on every new disclosure.